-
1
-
-
84892805731
-
Cancer statistics, 2014
-
Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29.
-
(2014)
CA Cancer J Clin
, vol.64
, pp. 9-29
-
-
Siegel, R.1
Ma, J.2
Zou, Z.3
Jemal, A.4
-
2
-
-
0029037784
-
Prognostic significance of capsular invasion and capsular penetration in patients with clinically localized prostate cancer undergoing radical prostatectomy
-
Theiss M, Wirth MP, Manseck A, Frohmuller HG. Prognostic significance of capsular invasion and capsular penetration in patients with clinically localized prostate cancer undergoing radical prostatectomy. Prostate 1995;27:13-7.
-
(1995)
Prostate
, vol.27
, pp. 13-17
-
-
Theiss, M.1
Wirth, M.P.2
Manseck, A.3
Frohmuller, H.G.4
-
3
-
-
84879459843
-
Positive margins after radical prostatectomy: Implications for failure and role of adjuvant treatment
-
Swanson GP, Lerner SP. Positive margins after radical prostatectomy: implications for failure and role of adjuvant treatment. Urol Oncol 2013;31:531-41.
-
(2013)
Urol Oncol
, vol.31
, pp. 531-541
-
-
Swanson, G.P.1
Lerner, S.P.2
-
4
-
-
77951880385
-
Positive surgical margins at radical prostatectomy predict prostate cancer specific mortality
-
Wright JL, Dalkin BL, True LD, Ellis WJ, Stanford JL, Lange PH, et al. Positive surgical margins at radical prostatectomy predict prostate cancer specific mortality. J Urol 2010;183:2213-8.
-
(2010)
J Urol
, vol.183
, pp. 2213-2218
-
-
Wright, J.L.1
Dalkin, B.L.2
True, L.D.3
Ellis, W.J.4
Stanford, J.L.5
Lange, P.H.6
-
5
-
-
0023547004
-
Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
-
Horoszewicz JS, Kawinski E, Murphy GP. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res 1987;7:927-35.
-
(1987)
Anticancer Res
, vol.7
, pp. 927-935
-
-
Horoszewicz, J.S.1
Kawinski, E.2
Murphy, G.P.3
-
6
-
-
0028631034
-
Sensitive nested reverse transcription polymerase chain reaction detection of circulating prostatic tumor cells: Comparison of prostate-specific membrane antigen and prostate-specific antigen-based assays
-
Israeli RS, Miller WH Jr, Su SL, Powell CT, Fair WR, Samadi DS, et al. Sensitive nested reverse transcription polymerase chain reaction detection of circulating prostatic tumor cells: comparison of prostate-specific membrane antigen and prostate-specific antigen-based assays. Cancer Res 1994;54:6306-10.
-
(1994)
Cancer Res
, vol.54
, pp. 6306-6310
-
-
Israeli, R.S.1
Miller, W.H.2
Su, S.L.3
Powell, C.T.4
Fair, W.R.5
Samadi, D.S.6
-
7
-
-
0034797419
-
A unique folate hydrolase, prostate-specific membrane antigen (PSMA): A target for immunotherapy?
-
Tasch J, Gong M, Sadelain M, Heston WD. A unique folate hydrolase, prostate-specific membrane antigen (PSMA): a target for immunotherapy? Crit Rev Immunol 2001;21:249-61.
-
(2001)
Crit Rev Immunol
, vol.21
, pp. 249-261
-
-
Tasch, J.1
Gong, M.2
Sadelain, M.3
Heston, W.D.4
-
8
-
-
68949116384
-
Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis
-
Mannweiler S, Amersdorfer P, Trajanoski S, Terrett JA, King D, Mehes G. Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis. Pathol Oncol Res 2009;15:167-72.
-
(2009)
Pathol Oncol Res
, vol.15
, pp. 167-172
-
-
Mannweiler, S.1
Amersdorfer, P.2
Trajanoski, S.3
Terrett, J.A.4
King, D.5
Mehes, G.6
-
9
-
-
0029154151
-
Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids
-
Troyer JK, Beckett ML, Wright GL Jr. Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int J Cancer 1995;62:552-8.
-
(1995)
Int J Cancer
, vol.62
, pp. 552-558
-
-
Troyer, J.K.1
Beckett, M.L.2
Wright, G.L.3
-
10
-
-
0346333234
-
Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer
-
Ross JS, Sheehan CE, Fisher HA, Kaufman RP Jr, Kaur P, Gray K, et al. Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res 2003;9:6357-62.
-
(2003)
Clin Cancer Res
, vol.9
, pp. 6357-6362
-
-
Ross, J.S.1
Sheehan, C.E.2
Fisher, H.A.3
Kaufman, R.P.4
Kaur, P.5
Gray, K.6
-
11
-
-
35048896107
-
Targeted treatment of prostate cancer
-
Wang X, Yin L, Rao P, Stein R, Harsch KM, Lee Z, et al. Targeted treatment of prostate cancer. J Cell Biochem 2007;102:571-9.
-
(2007)
J Cell Biochem
, vol.102
, pp. 571-579
-
-
Wang, X.1
Yin, L.2
Rao, P.3
Stein, R.4
Harsch, K.M.5
Lee, Z.6
-
12
-
-
0033168844
-
Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature
-
Chang SS, Reuter VE, Heston WD, Bander NH, Grauer LS, Gaudin PB. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res 1999;59:3192-8.
-
(1999)
Cancer Res
, vol.59
, pp. 3192-3198
-
-
Chang, S.S.1
Reuter, V.E.2
Heston, W.D.3
Bander, N.H.4
Grauer, L.S.5
Gaudin, P.B.6
-
13
-
-
0032740888
-
Prostate-specific membrane antigen is produced in tumor-associated neovasculature
-
Chang SS, O'Keefe DS, Bacich DJ, Reuter VE, Heston WD, Gaudin PB. Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res 1999;5:2674-81.
-
(1999)
Clin Cancer Res
, vol.5
, pp. 2674-2681
-
-
Chang, S.S.1
O'Keefe, D.S.2
Bacich, D.J.3
Reuter, V.E.4
Heston, W.D.5
Gaudin, P.B.6
-
14
-
-
0025912619
-
Immunoscintigraphy of prostatic cancer: Preliminary results with 111In-labeled monoclonal antibody 7E11-C5.3 (CYT-356)
-
Wynant GE, Murphy GP, Horoszewicz JS, Neal CE, Collier BD, Mitchell E, et al. Immunoscintigraphy of prostatic cancer: preliminary results with 111In-labeled monoclonal antibody 7E11-C5.3 (CYT-356). Prostate 1991;18:229-41.
-
(1991)
Prostate
, vol.18
, pp. 229-241
-
-
Wynant, G.E.1
Murphy, G.P.2
Horoszewicz, J.S.3
Neal, C.E.4
Collier, B.D.5
Mitchell, E.6
-
15
-
-
33645765986
-
Technology insight: Monoclonal antibody imaging of prostate cancer
-
Bander NH. Technology insight: monoclonal antibody imaging of prostate cancer. Nat Clin Pract Urol 2006;3:216-25.
-
(2006)
Nat Clin Pract Urol
, vol.3
, pp. 216-225
-
-
Bander, N.H.1
-
16
-
-
22044451179
-
Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer
-
Bander NH, Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol 2005;23:4591-601.
-
(2005)
J Clin Oncol
, vol.23
, pp. 4591-4601
-
-
Bander, N.H.1
Milowsky, M.I.2
Nanus, D.M.3
Kostakoglu, L.4
Vallabhajosula, S.5
Goldsmith, S.J.6
-
17
-
-
0141919750
-
Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen
-
Bander NH, Trabulsi EJ, Kostakoglu L, Yao D, Vallabhajosula S, Smith-Jones P, et al. Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. J Urol 2003;170:1717-21.
-
(2003)
J Urol
, vol.170
, pp. 1717-1721
-
-
Bander, N.H.1
Trabulsi, E.J.2
Kostakoglu, L.3
Yao, D.4
Vallabhajosula, S.5
Smith-Jones, P.6
-
18
-
-
84899103424
-
A prospective pilot study of (89)Zr-J591/prostate specific membrane antigen positron emission tomography in men with localized prostate cancer undergoing radical prostatectomy
-
Osborne JR, Green DA, Spratt DE, Fareedy SB, Robinson BD, Beattie BJ, et al. A prospective pilot study of (89)Zr-J591/prostate specific membrane antigen positron emission tomography in men with localized prostate cancer undergoing radical prostatectomy. J Urol 2013;191:1439-45.
-
(2013)
J Urol
, vol.191
, pp. 1439-1445
-
-
Osborne, J.R.1
Green, D.A.2
Spratt, D.E.3
Fareedy, S.B.4
Robinson, B.D.5
Beattie, B.J.6
-
19
-
-
84884536175
-
Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer
-
Tagawa ST, Milowsky MI, Morris M, Vallabhajosula S, Christos P, Akhtar NH, et al. Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clin Cancer Res 2013;19:5182-91.
-
(2013)
Clin Cancer Res
, vol.19
, pp. 5182-5191
-
-
Tagawa, S.T.1
Milowsky, M.I.2
Morris, M.3
Vallabhajosula, S.4
Christos, P.5
Akhtar, N.H.6
-
20
-
-
31344447699
-
High-affinity near-infrared fluorescent small-molecule contrast agents for in vivo imaging of prostate-specific membrane antigen
-
Humblet V, Lapidus R, Williams LR, Tsukamoto T, Rojas C, Majer P, et al. High-affinity near-infrared fluorescent small-molecule contrast agents for in vivo imaging of prostate-specific membrane antigen. Mol Imaging 2005;4:448-62.
-
(2005)
Mol Imaging
, vol.4
, pp. 448-462
-
-
Humblet, V.1
Lapidus, R.2
Williams, L.R.3
Tsukamoto, T.4
Rojas, C.5
Majer, P.6
-
21
-
-
49449111732
-
Synthesis and evaluation of technetium-99m- and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA)
-
Banerjee SR, Foss CA, Castanares M, Mease RC, Byun Y, Fox JJ, et al. Synthesis and evaluation of technetium-99m- and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA). J Med Chem 2008;51:4504-17.
-
(2008)
J Med Chem
, vol.51
, pp. 4504-4517
-
-
Banerjee, S.R.1
Foss, C.A.2
Castanares, M.3
Mease, R.C.4
Byun, Y.5
Fox, J.J.6
-
22
-
-
77954691424
-
68Ga-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer
-
Banerjee SR, Pullambhatla M, Byun Y, Nimmagadda S, Green G, Fox JJ, et al. 68Ga-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer. J Med Chem 2010;53:5333-41.
-
(2010)
J Med Chem
, vol.53
, pp. 5333-5341
-
-
Banerjee, S.R.1
Pullambhatla, M.2
Byun, Y.3
Nimmagadda, S.4
Green, G.5
Fox, J.J.6
-
23
-
-
70449724565
-
A low molecular weight PSMA-based fluorescent imaging agent for cancer
-
Chen Y, Dhara S, Banerjee SR, Byun Y, Pullambhatla M, Mease RC, et al. A low molecular weight PSMA-based fluorescent imaging agent for cancer. Biochem Biophys Res Commun 2009;390:624-9.
-
(2009)
Biochem Biophys Res Commun
, vol.390
, pp. 624-629
-
-
Chen, Y.1
Dhara, S.2
Banerjee, S.R.3
Byun, Y.4
Pullambhatla, M.5
Mease, R.C.6
-
24
-
-
58149098403
-
Radiohalogenated prostate-specific membrane antigen (PSMA)-based ureas as imaging agents for prostate cancer
-
Chen Y, Foss CA, Byun Y, Byun Y, Pullambhatla M, Mease RC, et al. Radiohalogenated prostate-specific membrane antigen (PSMA)-based ureas as imaging agents for prostate cancer. J Med Chem 2008;51:7933-43.
-
(2008)
J Med Chem
, vol.51
, pp. 7933-7943
-
-
Chen, Y.1
Foss, C.A.2
Byun, Y.3
Byun, Y.4
Pullambhatla, M.5
Mease, R.C.6
-
25
-
-
20344374435
-
Radiolabeled small-molecule ligands for prostate-specific membrane antigen: In vivo imaging in experimental models of prostate cancer
-
Foss CA, Mease RC, Fan H, Wang Y, Ravert HT, Dannals RF, et al. Radiolabeled small-molecule ligands for prostate-specific membrane antigen: in vivo imaging in experimental models of prostate cancer. Clin Cancer Res 2005;11:4022-8.
-
(2005)
Clin Cancer Res
, vol.11
, pp. 4022-4028
-
-
Foss, C.A.1
Mease, R.C.2
Fan, H.3
Wang, Y.4
Ravert, H.T.5
Dannals, R.F.6
-
26
-
-
79960301987
-
123I-MIP-1072, a small-molecule inhibitor of prostate-specific membrane antigen, is effective at monitoring tumor response to taxane therapy
-
Hillier SM, Kern AM, Maresca KP, Wang Y, Ravert HT, Dannals RF, et al. 123I-MIP-1072, a small-molecule inhibitor of prostate-specific membrane antigen, is effective at monitoring tumor response to taxane therapy. J Nucl Med 2011;52:1087-93.
-
(2011)
J Nucl Med
, vol.52
, pp. 1087-1093
-
-
Hillier, S.M.1
Kern, A.M.2
Maresca, K.P.3
Wang, Y.4
Ravert, H.T.5
Dannals, R.F.6
-
27
-
-
70149094319
-
Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer
-
Hillier SM, Maresca KP, Femia FJ, Marquis JC, Foss CA, Nguyen N, et al. Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. Cancer Res 2009;69:6932-40.
-
(2009)
Cancer Res
, vol.69
, pp. 6932-6940
-
-
Hillier, S.M.1
Maresca, K.P.2
Femia, F.J.3
Marquis, J.C.4
Foss, C.A.5
Nguyen, N.6
-
28
-
-
84881417445
-
99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer
-
Hillier SM, Maresca KP, Lu G, Merkin RD, Marquis JC, Zimmerman CN, et al. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer. J Nucl Med 2013;54:1369-76.
-
(2013)
J Nucl Med
, vol.54
, pp. 1369-1376
-
-
Hillier, S.M.1
Maresca, K.P.2
Lu, G.3
Merkin, R.D.4
Marquis, J.C.5
Zimmerman, C.N.6
-
29
-
-
84879355672
-
Development of tumor-targeted near infrared probes for fluorescence guided surgery
-
Kelderhouse LE, Chelvam V, Wayua C, Mahalingam S, Poh S, Kularatne SA, et al. Development of tumor-targeted near infrared probes for fluorescence guided surgery. Bioconjug Chem 2013;24:1075-80.
-
(2013)
Bioconjug Chem
, vol.24
, pp. 1075-1080
-
-
Kelderhouse, L.E.1
Chelvam, V.2
Wayua, C.3
Mahalingam, S.4
Poh, S.5
Kularatne, S.A.6
-
30
-
-
84871268152
-
Synthesis and biological evaluation of low molecular weight fluorescent imaging agents for the prostate-specific membrane antigen
-
Chen Y, Pullambhatla M, Banerjee SR, Byun Y, Stathis M, Rojas C, et al. Synthesis and biological evaluation of low molecular weight fluorescent imaging agents for the prostate-specific membrane antigen. Bioconjug Chem 2009;23:2377-85.
-
(2009)
Bioconjug Chem
, vol.23
, pp. 2377-2385
-
-
Chen, Y.1
Pullambhatla, M.2
Banerjee, S.R.3
Byun, Y.4
Stathis, M.5
Rojas, C.6
-
31
-
-
84870340190
-
Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer
-
Cho SY, Gage KL, Mease RC, Senthamizhchelvan S, Holt DP, Jeffrey-Kwanisai A, et al. Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer. J Nucl Med 2012;53:1883-91.
-
(2012)
J Nucl Med
, vol.53
, pp. 1883-1891
-
-
Cho, S.Y.1
Gage, K.L.2
Mease, R.C.3
Senthamizhchelvan, S.4
Holt, D.P.5
Jeffrey-Kwanisai, A.6
-
32
-
-
49449089475
-
N-[N-[(S)-1,3-Dicarboxypropyl]carbamoyl]-4-[18F]fluorobenzyl-L-cysteine, [18F]DCFBC: A new imaging probe for prostate cancer
-
Mease RC, Dusich CL, Foss CA, Senthamizhchelvan S, Holt DP, Jeffrey-Kwanisai A, et al. N-[N-[(S)-1,3-Dicarboxypropyl]carbamoyl]-4-[18F]fluorobenzyl-L-cysteine, [18F]DCFBC: a new imaging probe for prostate cancer. Clin Cancer Res 2008;14:3036-43.
-
(2008)
Clin Cancer Res
, vol.14
, pp. 3036-3043
-
-
Mease, R.C.1
Dusich, C.L.2
Foss, C.A.3
Senthamizhchelvan, S.4
Holt, D.P.5
Jeffrey-Kwanisai, A.6
-
33
-
-
84874820819
-
First-in-man evaluation of 2 high-affinity PSMA-avid small molecules for imaging prostate cancer
-
Barrett JA, Coleman RE, Goldsmith SJ, Vallabhajosula S, Petry NA, Cho S, et al. First-in-man evaluation of 2 high-affinity PSMA-avid small molecules for imaging prostate cancer. J Nucl Med 2013;54:380-7.
-
(2013)
J Nucl Med
, vol.54
, pp. 380-387
-
-
Barrett, J.A.1
Coleman, R.E.2
Goldsmith, S.J.3
Vallabhajosula, S.4
Petry, N.A.5
Cho, S.6
-
34
-
-
84898829722
-
Improving the biodistribution of PSMA-targeting tracers with a highly negatively charged linker
-
Huang SS, Wang X, Zhang Y, Doke A, Difilippo FP, Heston WD. Improving the biodistribution of PSMA-targeting tracers with a highly negatively charged linker. Prostate 2014;74:702-13.
-
(2014)
Prostate
, vol.74
, pp. 702-713
-
-
Huang, S.S.1
Wang, X.2
Zhang, Y.3
Doke, A.4
Difilippo, F.P.5
Heston, W.D.6
-
35
-
-
84859806938
-
Structure-activity relationships of 2′,5′-oligoadenylate analogue modifications of prostate-specific membrane antigen (PSMA) antagonists
-
Wang X, Tian H, Lee Z, Heston WD. Structure-activity relationships of 2′,5′-oligoadenylate analogue modifications of prostate-specific membrane antigen (PSMA) antagonists. Nucleosides Nucleotides Nucleic Acids 2012;31:432-44.
-
(2012)
Nucleosides Nucleotides Nucleic Acids
, vol.31
, pp. 432-444
-
-
Wang, X.1
Tian, H.2
Lee, Z.3
Heston, W.D.4
-
36
-
-
84865050506
-
A small molecule agonist of EphA2 receptor tyrosine kinase inhibits tumor cell migration in vitro and prostate cancer metastasis in vivo
-
Petty A, Myshkin E, Qin H, Guo H, Miao H, Tochtrop GP, et al. A small molecule agonist of EphA2 receptor tyrosine kinase inhibits tumor cell migration in vitro and prostate cancer metastasis in vivo. PLoS ONE 2012;7:e42120.
-
(2012)
PLoS ONE
, vol.7
, pp. e42120
-
-
Petty, A.1
Myshkin, E.2
Qin, H.3
Guo, H.4
Miao, H.5
Tochtrop, G.P.6
-
37
-
-
36949039181
-
2-5A ligands-a new concept for the treatment of prostate cancer
-
Cramer H, Okicki JR, Rho T, Wang X, Silverman RH, Heston WD. 2-5A ligands-a new concept for the treatment of prostate cancer. Nucleosides Nucleotides Nucleic Acids 2007;26:1471-7.
-
(2007)
Nucleosides Nucleotides Nucleic Acids
, vol.26
, pp. 1471-1477
-
-
Cramer, H.1
Okicki, J.R.2
Rho, T.3
Wang, X.4
Silverman, R.H.5
Heston, W.D.6
-
38
-
-
33947541693
-
Human glutamate carboxypeptidase II inhibition: Structures of GCPII in complex with two potent inhibitors, quisqualate and 2-PMPA
-
Mesters JR, Henning K, Hilgenfeld R. Human glutamate carboxypeptidase II inhibition: structures of GCPII in complex with two potent inhibitors, quisqualate and 2-PMPA. Acta Crystallogr D Biol Crystallogr 2007;63:508-13.
-
(2007)
Acta Crystallogr D Biol Crystallogr
, vol.63
, pp. 508-513
-
-
Mesters, J.R.1
Henning, K.2
Hilgenfeld, R.3
-
39
-
-
68749087539
-
Structural insight into the evolutionary and pharmacologic homology of glutamate carboxypeptidases II and III
-
Hlouchova K, Barinka C, Konvalinka J, Lubkowski J. Structural insight into the evolutionary and pharmacologic homology of glutamate carboxypeptidases II and III. FEBS J 2009;276:4448-62.
-
(2009)
FEBS J
, vol.276
, pp. 4448-4462
-
-
Hlouchova, K.1
Barinka, C.2
Konvalinka, J.3
Lubkowski, J.4
-
40
-
-
3843113671
-
Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer
-
Ghosh A, Heston WD. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem 2004;91:528-39.
-
(2004)
J Cell Biochem
, vol.91
, pp. 528-539
-
-
Ghosh, A.1
Heston, W.D.2
-
41
-
-
0345306595
-
A novel cytoplasmic tail MXXXL motif mediates the internalization of prostate-specific membrane antigen
-
Rajasekaran SA, Anilkumar G, Oshima E, Bowie JU, Liu H, Heston W, et al. A novel cytoplasmic tail MXXXL motif mediates the internalization of prostate-specific membrane antigen. Mol Biol Cell 2003;14:4835-45.
-
(2003)
Mol Biol Cell
, vol.14
, pp. 4835-4845
-
-
Rajasekaran, S.A.1
Anilkumar, G.2
Oshima, E.3
Bowie, J.U.4
Liu, H.5
Heston, W.6
-
42
-
-
78149285690
-
A targeted low molecular weight near-infrared fluorescent probe for prostate cancer
-
Liu T, Wu LY, Hopkins MR, Choi JK, Berkman CE. A targeted low molecular weight near-infrared fluorescent probe for prostate cancer. Bioorg Med Chem Lett 2010;20:7124-6.
-
(2010)
Bioorg Med Chem Lett
, vol.20
, pp. 7124-7126
-
-
Liu, T.1
Wu, L.Y.2
Hopkins, M.R.3
Choi, J.K.4
Berkman, C.E.5
-
43
-
-
80051777429
-
Targeted, activatable, in vivo fluorescence imaging of prostate-specific membrane antigen (PSMA) positive tumors using the quenched humanized J591 antibody-indocyanine green (ICG) conjugate
-
Nakajima T, Mitsunaga M, Bander NH, Heston WD, Choyke PL, Kobayashi H. Targeted, activatable, in vivo fluorescence imaging of prostate-specific membrane antigen (PSMA) positive tumors using the quenched humanized J591 antibody-indocyanine green (ICG) conjugate. Bioconjug Chem 2011;22:1700-5.
-
(2011)
Bioconjug Chem
, vol.22
, pp. 1700-1705
-
-
Nakajima, T.1
Mitsunaga, M.2
Bander, N.H.3
Heston, W.D.4
Choyke, P.L.5
Kobayashi, H.6
-
44
-
-
67349230887
-
Intraoperative radioguidance with a portable gamma camera: A novel technique for laparoscopic sentinel node localisation in urological malignancies
-
Vermeeren L, Valdes Olmos RA, Meinhardt W, Bex A, van der Poel HG, Vogel WV, et al. Intraoperative radioguidance with a portable gamma camera: a novel technique for laparoscopic sentinel node localisation in urological malignancies. Eur J Nucl Med Mol Imaging 2009;36:1029-36.
-
(2009)
Eur J Nucl Med Mol Imaging
, vol.36
, pp. 1029-1036
-
-
Vermeeren, L.1
Valdes Olmos, R.A.2
Meinhardt, W.3
Bex, A.4
Van Der Poel, H.G.5
Vogel, W.V.6
-
45
-
-
33750538688
-
Performance tests of two portable mini gamma cameras for medical applications
-
Sanchez F, Fernandez MM, Gimenez M, Benlloch JM, Rodríguez-Alvarez MJ, García de Quirós F, et al. Performance tests of two portable mini gamma cameras for medical applications. Med Phys 2006;33:4210-20.
-
(2006)
Med Phys
, vol.33
, pp. 4210-4220
-
-
Sanchez, F.1
Fernandez, M.M.2
Gimenez, M.3
Benlloch, J.M.4
Rodríguez-Alvarez, M.J.5
García De Quirós, F.6
-
46
-
-
0030065584
-
Enhanced optical imaging of human gliomas and tumor margins
-
Haglund MM, Berger MS, Hochman DW. Enhanced optical imaging of human gliomas and tumor margins. Neurosurgery 1996;38:308-17.
-
(1996)
Neurosurgery
, vol.38
, pp. 308-317
-
-
Haglund, M.M.1
Berger, M.S.2
Hochman, D.W.3
-
47
-
-
77957977603
-
Multimodality intraoperative MRI for brain tumor surgery
-
Colen RR, Kekhia H, Jolesz FA. Multimodality intraoperative MRI for brain tumor surgery. Expert Rev Neurother 2010;10:1545-58.
-
(2010)
Expert Rev Neurother
, vol.10
, pp. 1545-1558
-
-
Colen, R.R.1
Kekhia, H.2
Jolesz, F.A.3
-
48
-
-
80053989452
-
Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-alpha targeting: First in-human results
-
van Dam GM, Themelis G, Crane LM, Harlaar NJ, Pleijhuis RG, Kelder W, et al. Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-alpha targeting: first in-human results. Nat Med 2011;17:1315-9.
-
(2011)
Nat Med
, vol.17
, pp. 1315-1319
-
-
Van Dam, G.M.1
Themelis, G.2
Crane, L.M.3
Harlaar, N.J.4
Pleijhuis, R.G.5
Kelder, W.6
-
49
-
-
0031972670
-
Patient-reported symptoms after primary therapy for early prostate cancer: Results of a prospective cohort study
-
Talcott JA, Rieker P, Clark JA, Weeks JC, Beard CJ, Wishnow KI, et al. Patient-reported symptoms after primary therapy for early prostate cancer: results of a prospective cohort study. J Clin Oncol 1998;16:275-83.
-
(1998)
J Clin Oncol
, vol.16
, pp. 275-283
-
-
Talcott, J.A.1
Rieker, P.2
Clark, J.A.3
Weeks, J.C.4
Beard, C.J.5
Wishnow, K.I.6
-
50
-
-
84878619701
-
Robotic retroperitoneal transvaginal natural orifice translumenal endoscopic surgery (NOTES) nephrectomy: Feasibility study in a cadaver model
-
Laydner H, Autorino R, Isac W, Khalifeh A, Panumatrassamee K, Kassab A, et al. Robotic retroperitoneal transvaginal natural orifice translumenal endoscopic surgery (NOTES) nephrectomy: feasibility study in a cadaver model. Urology 2012;81:1232-7.
-
(2012)
Urology
, vol.81
, pp. 1232-1237
-
-
Laydner, H.1
Autorino, R.2
Isac, W.3
Khalifeh, A.4
Panumatrassamee, K.5
Kassab, A.6
|